Abstract
BackgroundAdalimumab 40mg/14days (ADA14) has demonstrated efficacy in patients with rheumatoid arthritis (RA), psoriatic arthropathy (PA) and ankylosing spondylitis (AS). In certain patients in sustained clinical remission with ADA14, a dose...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
